# OnCo record rtk-activation (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/rtk-activation/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "rtk-activation" ;
  schema:name "Receptor tyrosine kinase activation"@en ;
  schema:description "Growth-factor receptors are antennas on the cell surface that pair up when a signal lands and switch on the growth relays inside. Cancers mutate, multiply, or fuse these antennas so they broadcast 'grow' with no signal at all. Most targeted drugs, antibodies and ADCs start here."@en ;
  schema:url <https://onco.cc/pathways/rtk-activation/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Receptor_tyrosine_kinase> ;
  schema:citation <https://doi.org/10.1016/j.cell.2010.06.011> ;
  onco:tag "mechanism", "mechanics-atlas" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/gist/>, <https://onco.cc/cancers/thyroid/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/gallbladder/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/her3/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/ret/>, <https://onco.cc/targets/ros1/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/fgfr2/>, <https://onco.cc/targets/kit/>, <https://onco.cc/targets/flt3/>, <https://onco.cc/targets/pdgfra/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/pik3ca/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/capmatinib-tepotinib/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/zongertinib/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/zenocutuzumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/patritumab-deruxtecan/>, <https://onco.cc/drugs/telisotuzumab-vedotin/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/jak-stat/>, <https://onco.cc/pathways/resistance-routes-map/> ;
  onco:terms <https://onco.cc/terms/oncogene-addiction/>, <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/egfr-exon19-l858r/>, <https://onco.cc/terms/egfr-exon20-insertion/>, <https://onco.cc/terms/c797s/>, <https://onco.cc/terms/met-amplification/>, <https://onco.cc/terms/egfrviii/>, <https://onco.cc/terms/her2-low/>, <https://onco.cc/terms/adcc/> .